Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE
Background: Lutetium-177 (177Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritone...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2025-07-01
|
| Series: | Endocrine Oncology |
| Subjects: | |
| Online Access: | https://eo.bioscientifica.com/view/journals/eo/5/1/EO-25-0033.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849432548271194112 |
|---|---|
| author | Eleonora Pelle Taymeyah Al-Toubah Ghassan El-Haddad Brian Morse Bhavana Konda Vineeth Sukrithan Jonathan Strosberg |
| author_facet | Eleonora Pelle Taymeyah Al-Toubah Ghassan El-Haddad Brian Morse Bhavana Konda Vineeth Sukrithan Jonathan Strosberg |
| author_sort | Eleonora Pelle |
| collection | DOAJ |
| description | Background: Lutetium-177 (177Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described. We investigated the potential for intestinal ischemia in 177Lu-DOTATATE-treated patients. Methods: Clinical records were reviewed of patients with midgut NETs treated with 177Lu-DOTATATE at the Moffitt Cancer Center between April 2018 and December 2022 and at The Ohio State University between December 2017 and October 2020. Results: Among the cases reviewed, we identified three patients who developed bowel ischemia/perforation shortly after their initial treatment with 177Lu-DOTATATE. All patients had metastatic small bowel NET with prominent mesenteric mass encasing/obstructing the mesenteric vessels and preexisting symptoms of postprandial abdominal pain. Conclusion: Acute bowel ischemia may be a rare complication of PRRT in patients with mesenteric arterial or venous obstruction from mesenteric metastasis. |
| format | Article |
| id | doaj-art-0f86869aee774c2aafeb65e895e99c3c |
| institution | Kabale University |
| issn | 2634-4793 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Oncology |
| spelling | doaj-art-0f86869aee774c2aafeb65e895e99c3c2025-08-20T03:27:19ZengBioscientificaEndocrine Oncology2634-47932025-07-015110.1530/EO-25-00331Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATEEleonora Pelle0Taymeyah Al-Toubah1Ghassan El-Haddad2Brian Morse3Bhavana Konda4Vineeth Sukrithan5Jonathan Strosberg6Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USADepartment of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USADepartment of Diagnostic Imaging and Interventional Radiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USADepartment of Diagnostic Imaging and Interventional Radiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USADivision of Medical Oncology, Department of Internal Medicine, Ohio State University College of Medicine, Columbus, Ohio, USADivision of Medical Oncology, Department of Internal Medicine, Ohio State University College of Medicine, Columbus, Ohio, USADepartment of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USABackground: Lutetium-177 (177Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described. We investigated the potential for intestinal ischemia in 177Lu-DOTATATE-treated patients. Methods: Clinical records were reviewed of patients with midgut NETs treated with 177Lu-DOTATATE at the Moffitt Cancer Center between April 2018 and December 2022 and at The Ohio State University between December 2017 and October 2020. Results: Among the cases reviewed, we identified three patients who developed bowel ischemia/perforation shortly after their initial treatment with 177Lu-DOTATATE. All patients had metastatic small bowel NET with prominent mesenteric mass encasing/obstructing the mesenteric vessels and preexisting symptoms of postprandial abdominal pain. Conclusion: Acute bowel ischemia may be a rare complication of PRRT in patients with mesenteric arterial or venous obstruction from mesenteric metastasis.https://eo.bioscientifica.com/view/journals/eo/5/1/EO-25-0033.xmlprrtbowel ischemiasmall bowel netmesenteric lesions |
| spellingShingle | Eleonora Pelle Taymeyah Al-Toubah Ghassan El-Haddad Brian Morse Bhavana Konda Vineeth Sukrithan Jonathan Strosberg Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE Endocrine Oncology prrt bowel ischemia small bowel net mesenteric lesions |
| title | Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE |
| title_full | Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE |
| title_fullStr | Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE |
| title_full_unstemmed | Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE |
| title_short | Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE |
| title_sort | risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177lu dotatate |
| topic | prrt bowel ischemia small bowel net mesenteric lesions |
| url | https://eo.bioscientifica.com/view/journals/eo/5/1/EO-25-0033.xml |
| work_keys_str_mv | AT eleonorapelle riskofbowelischemiainpatientswithmesentericneuroendocrinetumorsaftertreatmentwith177ludotatate AT taymeyahaltoubah riskofbowelischemiainpatientswithmesentericneuroendocrinetumorsaftertreatmentwith177ludotatate AT ghassanelhaddad riskofbowelischemiainpatientswithmesentericneuroendocrinetumorsaftertreatmentwith177ludotatate AT brianmorse riskofbowelischemiainpatientswithmesentericneuroendocrinetumorsaftertreatmentwith177ludotatate AT bhavanakonda riskofbowelischemiainpatientswithmesentericneuroendocrinetumorsaftertreatmentwith177ludotatate AT vineethsukrithan riskofbowelischemiainpatientswithmesentericneuroendocrinetumorsaftertreatmentwith177ludotatate AT jonathanstrosberg riskofbowelischemiainpatientswithmesentericneuroendocrinetumorsaftertreatmentwith177ludotatate |